AB174. Erectile dysfunction and usage of PDE5-inhibitors in male partner of infertile couple

نویسندگان

  • Seung-Hun Song
  • Dong Suk Kim
  • Sung Won Kwon
  • Tai Young Ahn
چکیده

Transl Androl Urol, Vol 3, Suppl 1 September 2014 www.amepc.org/tau © Translational Andrology and Urology. All rights reserved. Results: Total cholesterol was significantly decreased after 6 months by TRT compared to before TRT (183.7±33.9, 175.5±33.1, P=0.001). Triglycerides was also significantly decreased after 6 months (147.2±84.1, 131.2±62.7, P=0.009). TC and TGs were decreased after 12 months. However, there were no changes in LDL-C at 6 months (114.2±27.7, 110.2±30.1, P=0.44) and 12 months (114.2±27.7, 110.8±25.7, P=0.159) after TRT. The change was not found in HDL-C at 6 and 12 months (50.2±13.7, 50.1±14.6, 49.5±13.9). There was no increase in PSA with treatment at 6 months, however the increase was found at 12 months (0.85±0.58, 1.17±1.2, P=0.002). Conclusions: TRT has the efficacy to reduce total cholesterol and triglycerides. But LDL-C and HDL-C were not changed at 6 and 12 months after TRT.

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Usage and perceptions of phosphodiesterase type 5 inhibitors among the male partners of infertile couples

OBJECTIVE We aimed to investigate the prevalence of erectile dysfunction (ED) and the usage of phosphodiesterase type 5 (PDE5) inhibitors for ED treatment in infertile couples. METHODS A total of 260 male partners in couples reporting infertility lasting at least 1 year were included in this study. In addition to an evaluation of infertility, all participants completed the International Index...

متن کامل

Toward a new ‘EPOCH’: optimising treatment outcomes with phosphodiesterase type 5 inhibitors for erectile dysfunction

Despite the marked adverse impacts of erectile dysfunction (ED) on quality of life and well-being, many patients (and/or their partners) do not seek medical attention for this problem, do not receive treatment or discontinue such treatment even when it has effectively restored erectile responses to sexual stimulation. Phosphodiesterase type 5 (PDE5) inhibitors are considered first-line therapie...

متن کامل

Tadalafil Once-Daily: Patient and Partner Perspective in the Management of Erectile Dysfunction

Phosphodiesterase type 5 (PDE5) inhibitors are arguably the gold standard for treatment of erectile dysfunction in men. While all three PDE5 inhibitors approved for use in the U.S. are effective in treating ED, they possess different characteristics. Tadalafil differs from both sildenafil and vardenafil in its long half-life, which makes it ideal for daily dosing. This regimen has been shown to...

متن کامل

Tadalafil once daily in the management of erectile dysfunction: patient and partner perspectives

Erectile dysfunction (ED) is a prevalent condition that affects men and their partners. Significant improvements in the sexual lives of these couples have been achieved with the introduction of phosphodiesterase 5 (PDE5) inhibitors. A PDE5 inhibitor is now widely recognized as the first-line therapy for the majority of men with ED. Currently, three PDE5 inhibitors - sildenafil, tadalafil and va...

متن کامل

Patient preference and satisfaction in erectile dysfunction therapy: a comparison of the three phosphodiesterase-5 inhibitors sildenafil, vardenafil and tadalafil

Erectile dysfunction (ED) is a problem that may affect up to 52% of men between the ages of 40 and 70. It can be distressing because of its negative effect on self-esteem, quality of life, and interpersonal relationships. Oral phosphodiesterase-5 inhibitors (PDE5 inhibitors) are now the first choice of treatment in ED. The availability of three (sildenafil citrate, tadalafil, and vardenafil) we...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:

دوره 3  شماره 

صفحات  -

تاریخ انتشار 2014